Stay updated with breaking news from Recode Therapeutics. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
– Phase 1 trial to evaluate safety and tolerability of a single ascending dose of RCT1100, an inhaled mRNA-based genetic medicine– First clinical-stage candidate from ReCode’s proprietary SORT LNP delivery platform designed to restore ciliary function in the lungs of people with PCD caused by pathogenic mutations in...
Cancer continues to be a hot area of investment, and it’s the therapeutic focus of several biotech companies that have closed recent rounds of financing. Meanwhile, the investment arm of a big pharmaceutical company has an infusion of new cash to deploy in therapeutic and digital investments.
RTP-based AskBio has signed a multi-year research collaboration and option agreement with Bay-area firm ReCode Therapeutics to develop gene-editing technology for driving new precision therapies.
Cystic fibrosis is quickly becoming the most prevalent genetic illness in every region of the world. According to the Cystic Fibrosis Patient Registry, more...